<sod>The protein is the target for the [[antibody-drug conjugate]] ASG-15ME which is in phase 1 clinical trials for [[urothelial cancer]].<ref name=Ph1>{{cite web | url = http://www.businesswire.com/news/home/20161007005357/en/Seattle-Genetics-Agensys-Affiliate-Astellas-Highlight-Promising | title = Enfortumab Vedotin (ASG-22ME) and ASG-15ME Phase 1 Data in Metastatic Urothelial Cancer | date = October 2016 | author = Seattle Genetics and Agensys, an Affiliate of Astellas }}</ref><eod>
<sod>The protein is the target for the [[antibody-drug conjugate]] ASG-15ME which is in phase 1 clinical trials for [[urothelial cancer]].<ref name=Ph1>{{cite web | url = http://www.businesswire.com/news/home/20161007005357/en/Seattle-Genetics-Agensys-Affiliate-Astellas-Highlight-Promising | title = Interim Analysis of a Phase 1 Dose Escalation Trial of ASG-22CE (ASG-22ME; enfortumab vedotin), an Antibody-Drug Conjugate (ADC) in Patients with Metastatic Urothelial Cancer | work = Poster Abstract #788P,  European Society for Medical Oncology (ESMO) Congress, Copenhagen | date = October 2016 | author = Seattle Genetics and Agensys, an Affiliate of Astellas }}</ref><eod>